07:00 , Jul 18, 2016 |  BC Week In Review  |  Clinical News

ALXN1007: Interim Phase IIa data

Interim data from 13 evaluable patients with newly diagnosed acute GvHD of the lower gastrointestinal tract in an open-label, U.S. and French Phase IIa trial showed that once-weekly 10 mg/kg ALXN1007 plus methylprednisolone for 8...
07:00 , Jul 18, 2016 |  BC Week In Review  |  Clinical News

ALXN1007: Interim Phase IIa data

Interim data from 13 evaluable patients with newly diagnosed acute GvHD of the lower gastrointestinal tract in an open-label, U.S. and French Phase IIa trial showed that once-weekly 10 mg/kg ALXN1007 plus methylprednisolone for 8...
07:00 , May 18, 2015 |  BioCentury  |  Strategy

Alexion executes

The proposed acquisition of Synageva BioPharma Corp. is Alexion Pharmaceuticals Inc .'s biggest move to date under a four-year-old plan to diversify its portfolio. The plan, announced in 2011, includes expanding Soliris eculizumab beyond paroxysmal...
08:00 , Feb 20, 2012 |  BC Week In Review  |  Clinical News

ALXN1007: Phase I started

Alexion disclosed in its 4Q11 earnings that it began a double-blind, placebo-controlled, U.S. Phase I trial to evaluate 0.06, 0.1, 0.3, 1, 3, 6 and 10 mg/kg IV ALXN1007 in about 56 healthy volunteers. Alexion...